Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17729471 | 0.89 | MAPT (0.52) | RORCMAPTUSP30NR1H2TACR1 | |
| SCHEMBL17541957 | 0.86 | RORC (0.49) | RORCMAPTUSP30 | |
| SCHEMBL26105375 | 0.77 | RORC (0.43) | RORCUSP30PDE4BNR1H2TACR1 | |
| SCHEMBL26187054 | 0.77 | USP30 (0.45) | RORCUSP30PDE4BGPR119 | |
| SCHEMBL26187095 | 0.77 | USP30 (0.45) | RORCUSP30PDE4BGPR119 | |
| SCHEMBL17542065 | 0.77 | SMN1; SMN2 (0.52) | MAPTUSP30 | |
| SCHEMBL30324497 | 0.76 | RORC (0.42) | RORCUSP30PDE4BTACR1GPR119 | |
| SCHEMBL23211982 | 0.76 | MAPT (0.56) | MAPTKDM4EGPR119 | |
| SCHEMBL30324512 | 0.75 | GPR119 (0.46) | RORCGPR119 | |
| SCHEMBL24111414 | 0.75 | GPR119 (0.46) | RORCGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018216822-A1 | NOVEL IMIDAZOLE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-29 | — | — | WO | disclosed |